Immunome Doses First Patient in Phase 1 Trial of FAP-Targeted Radioligand Therapy IM-3050 — Immunome, Inc.

Event summary

Immunome dosed the first patient in a Phase 1 trial of IM-3050, a FAP-targeted radioligand therapy for advanced solid tumors.
The open-label, multicenter study will evaluate safety, tolerability, and preliminary anti-tumor activity.
IM-3050 delivers radioactive lutetium-177 to FAP-expressing cells, leveraging a bystander effect to target tumor microenvironment.
Immunome's pipeline includes varegacestat (NDA submitted), IM-1021, and IM-1617 alongside IM-3050.

The big picture

Immunome’s Phase 1 trial of IM-3050 underscores the growing focus on radioligand therapies targeting tumor microenvironments. With FAP expressed in 75% of solid tumors, IM-3050 could carve out a niche if early safety and efficacy signals hold. The company’s multi-pronged pipeline strategy positions it as a player in targeted oncology, though execution risks remain high.

What we're watching

Clinical Progress: How IM-3050's Phase 1 data will shape its path forward, particularly in dose escalation and expansion.
Competitive Positioning: Whether Immunome can differentiate IM-3050 in the crowded radioligand therapy space.
Regulatory Momentum: The pace at which Immunome advances its other candidates, including varegacestat's NDA review.